SELVEDge
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 33 patients (estimated)
- Sponsors
- University of Miami
- Collaborators
- Karyopharm Therapeutics
- Tags
- BCL-2 Inhibitor, Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1309
- NCT Identifier
- NCT05530421
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.